Skip to main content
AgileMD logo

AgileMD

AgileMD is a clinical decision support software company, driven to improve patient outcomes by making evidence-based care universally accessible. Since its founding at the University of Chicago, their work has been evaluated in 80 peer-reviewed publications and the company has received nearly $3 million in federal funding from the U.S. Department Health & Human Services (HHS). AgileMD’s clinical pathways and FDA-cleared early warning device, eCART, have been used by over 135,000 providers in more than 400 U.S. hospitals in the care of over 4 million patient encounters, including at some of the nation’s leading community and research centers.

Founded
2011
Employees
—
HQ
San Francisco, CA, USA
Website
https://www.agilemd.com

AI Solutions

1 solution available

Filter
eCARTv5 Clinical Deterioration Suite logo

eCARTv5 Clinical Deterioration Suite

AgileMDAgileMD

eCART is a software product that provides automated risk stratification and early warning for impending patient deterioration, signified as the composite outcome of death or ICU transfer. It is intended to be used on hospitalized ward patients 18 years of age or older by trained medical professionals. As a clinical decision support device, eCART’s risk score and trend analysis is intended to aid clinical teams in identifying which patients are most likely to clinically deteriorate. eCART provides additional information and does not replace the standard of care or clinical judgment. eCART scoring is initiated by the documentation of any vital sign on an adult ward patient. The device calculates risk only from validated EHR data, such as vitals that have been confirmed by a registered nurse (RN); unvalidated data streaming from monitors/devices will not be used until confirmed by a healthcare professional. The product predictions are for reference only and no therapeutic decisions should be made based solely on the eCART scores. See FDA 510(k) summary. eCART has repeatedly been found to have the highest performance metrics when compared to other early warning scores. In the initial multicenter validation study, involving nearly two million patient encounters, eCART had an AUROC of 0.834 (95% CI, 0.834–0.835) for predicting clinical deterioration within 24 hours, significantly outperforming MEWS and NEWS. In a second multicenter study eCART outperformed not only MEWS and NEWS but also the Rothman Index and Epic’s Deterioration Index, with and AUROC of 0.895 (95% CI, 0.891-0.900). Further, eCART is the only early warning system that includes not only a predictive analytic, but fully integrated EHR clinical workflows in the form of customizable pathways.

Details